Navigation Links
Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
Date:10/10/2011

nds towards benefit for lung function measures. The Forced Expiratory Volume in one second (FEV1) decreased in the placebo group as compared to baseline at 26 weeks (change: -5.6%; p=0.0582) with no such deterioration being observed in the AIMSPRO treated group. Similarly, the Forced Vital Capacity (FVC) was observed to decrease in the placebo group as compared to baseline at 26 weeks (change: -5.6%, p=0.1038), but not in the AIMSPRO treated group, where the FVC showed an increase (change:+1.8%, p=0.3225).

"Although requiring further confirmatory studies, these results are quite exciting, especially when compared to what has been seen in other pilot trials in scleroderma as there is a clear unmet medical need for patients suffering with this life-threatening disease" said Professor Christopher Denton, Professor of Experimental Rheumatology at the Royal Free Hospital in London, United Kingdom, the principal investigator for the trial. "The important value of the safety data from such a well-conducted trial in such a serious disease is clear, apart from the signals of therapeutic benefit."

Daval's Clinical and Scientific Director, Professor Syed Haq commented, "This study, conducted at one of the world's leading scleroderma centres, was an important first step towards understanding whether AIMSPRO could significantly help patients with diffuse scleroderma and potential overlapping connective tissue disorders, for which there is no cure, by arresting the disease even in its latter stages. AIMSPRO has been shown to be well-tolerated and safe and with the several positive therapeutic signals demonstrated, some of which were significant, it certainly warrants further investigation on a larger scale to determine the full efficacy of AIMSPRO in Late Stage Established Diffuse Cutaneous Systemic Sclerosis."

At the completion of the 26 week period of the study, AIMSPRO was offered to the patients on a compassionate
'/>"/>

SOURCE Daval International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... KALAMAZOO, Mich. , June 29, 2015 /PRNewswire/ ... Association and American Stroke Association give hope for ... patients who experience an acute ischemic stroke each ... of the key products used in the clinical ... The new AHA/ASA guidelines strongly recommend endovascular ...
(Date:6/29/2015)... , June 29, 2015 ... positive preliminary results from its BVX-006 Phase II clinical ... vaccine. In this trial, M-001 was injected intramuscularly to ... by an administration of the 2014/15 season trivalent influenza ... be safe and well tolerated and induced humoral immune ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
Breaking Medicine Technology:New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3
... JERUSALEM, Oct. 13, 2011 IDenta Corp. (OTC: IDTA) CEO ... Shoham stated, "We are succeeding in making sales in many ... products. We have received an order for 2000 ... http://www.gksolutions.com.au/ In the past several ...
... Association for Homecare urges the Joint Select Committee on ... cuts that will restrict access to home medical ... Over the years, homecare has broadened health care access ... the health care system by keeping seniors and people ...
Cached Medicine Technology:International Drug & Explosives Detection Company IDenta Corp. Receives Order From Australia 2American Association for Homecare Calls on Joint Deficit Committee in Congress to Preserve Homecare Access for Millions of Americans 2
(Date:6/29/2015)... Milwaukee, Wisconsin (PRWEB) , ... June 29, 2015 ... ... thrilled with the news that the European Medicines Agency (EMA) has granted accelerated ... , “Melanoma remains a global public health threat and the approval of nivolumab ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... products, announces the Fresh Plus Diaper, a baby invention that makes parenthood less ... is projected to reach a market value of USD 52.2 billion in 2017," ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... filed against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in ... Case Management Conference is to be convened on Thursday, July 23rd at 12:00 ...
(Date:6/29/2015)... ... 2015 , ... OR Manager announced Monday the launch of an enhanced ... a redesigned logo and weekly eLetter. The website contains the same informational articles, products, ... to navigate. , In addition to a refreshed look, http://www.ormanager.com now ...
(Date:6/29/2015)... MI (PRWEB) , ... June 29, 2015 , ... Celebrities ... perfect ten and have flawless skin all summer long and beyond. People don’t ... simple steps to slow the aging process, maintain an even skin tone, avoid breakouts, ...
Breaking Medicine News(10 mins):Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:OR Manager Launches New Website 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 3
... terms, anesthesia-associated mortality has risen again. The reasons for ... older and multimorbid patients and surgical procedures that would ... result of a selective literature review of Andr Gottschalk,s ... current issue of Deutsches rzteblatt International ( ...
... of The Gerontologist urges aging ... in their work. The publication also identifies research priorities ... in addition to providing several strategies that scholars can ... that non-white minorities will make up 42 percent of ...
... News) -- New research links medical problems caused by blood ... storage. The findings suggest that a better way to store ... high amounts of blood can lead to complications, including infection, ... Mark T. Gladwin in a news release from Wake Forest ...
... (NNI) released four reports that are the result ... issues in the nanotechnology environmental, health, and safety ... part of an ongoing strategy to coordinate nanotechnology-related ... and the Federal Government to share the latest ...
... , THURSDAY, July 21 (HealthDay News) -- The ... exhaustion, increases with age, experts at the U.S. National Institute ... researchers explained, they are less able to adapt to high ... a result, the heat might exacerbate any medical conditions they ...
... July 20 (HealthDay News) -- In a long-awaited move, ... the blood thinner Brilinta (ticagrelor) for use in patients ... for heart attack and death. Acute coronary syndromes ... attack linked to lowered blood flow to the heart, ...
Cached Medicine News:Health News:Minority participants crucial to effective aging studies 2Health News:Blood Stored Too Long May Threaten Patient Safety 2Health News:NNI releases 4 workshop reports from the nanoEHS Series 2Health News:Elderly at Greater Risk for Heat Stroke, Experts Warn 2Health News:FDA Approves Blood Thinner Brilinta for Heart Patients 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: